The COVID-19 monoclonal antibody therapy Evusheld may not prevent COVID-19 caused by certain variants of the virus, the Food and Drug Administration announced this week. For details, see the updated fact sheet for health care providers
 
FDA last year authorized the combination monoclonal antibody therapy for emergency use to help prevent COVID-19 in certain adults and children with compromised immune systems or a history of severe adverse reaction to a COVID-19 vaccine or its components. FDA continues to recommend Evusheld to prevent COVID-19 as it still offers protection against many circulating variants, but encourages patients to be prepared to test and seek immediate treatment if they experience COVID-19 symptoms. The agency also continues to recommend that people who can get vaccinated and boosted to prevent COVID-19.
 

Related News Articles

Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…